Spring Bank Pharma shares slide 45% premarket after it halts trial of treatment for hepatitis B virus

Spring Bank Pharmaceutical Inc.'s shares SBPH, -0.69% slid 45% in premarket trade Thursday, after the clinical-stage biopharma company said it has stopped dosing patients in a trial of a treatment for chronic hepatitis B virus, or HBV.